0000903423-19-000235.txt : 20190530 0000903423-19-000235.hdr.sgml : 20190530 20190530174738 ACCESSION NUMBER: 0000903423-19-000235 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190528 FILED AS OF DATE: 20190530 DATE AS OF CHANGE: 20190530 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GLAXOSMITHKLINE PLC CENTRAL INDEX KEY: 0001131399 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: X0 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 19867874 BUSINESS ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS BUSINESS PHONE: 011442080475000 MAIL ADDRESS: STREET 1: 980 GREAT WEST ROAD CITY: BRENTFORD MIDDLESEX STATE: X0 ZIP: TW8 9GS ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 4 1 glaxo.xml OWNERSHIP DOCUMENT X0306 4 2019-05-28 0 0001761612 BICYCLE THERAPEUTICS plc BCYC 0001131399 GLAXOSMITHKLINE PLC 980 GREAT WEST ROAD BRENTFORD MIDDLESEX X0 TW8 9GS UNITED KINGDOM 1 0 1 0 Ordinary Shares 2019-05-28 4 C 0 893195 A 893195 I See Footnote Ordinary Shares 2019-05-28 4 C 0 636366 A 1529561 I See Footnote Ordinary Shares 2019-05-28 4 P 0 385714 14.00 A 1915275 I See Footnote Series A Preferred Shares 2019-05-28 4 C 0 625049 0 D Ordinary Shares 893195 0 I See Footnote Series B1 Preferred Shares 2019-05-28 4 C 0 445323 0 D Ordinary Shares 636366 0 I See Footnote S.R. One, Limited acquired 385,714 Common Stock of Bicycle Therapeutics Limited (the "Issuer") in connection with the Issuer's initial public offering. The Series A Preferred Shares and the Series B1 Preferred Shares were converted into 1.429 shares of ordinary shares upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Shares and the Series B1 Preferred Shares were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. The shares reported herein are held of record by S.R. One, Limited, an indirect,wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person"). /s/ Victoria Whyte 2019-05-29